OnKure Therapeutics (OKUR) Retained Earnings (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Retained Earnings for 7 consecutive years, with $416.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 57.78% year-over-year to $416.9 million; the trailing twelve-month figure through Jun 2026 stood at $416.9 million (up 57.78% YoY), and the FY2025 full-year result was $270.4 million, up 4.59% from the prior year.
• Retained Earnings climbed to $416.9 million in Q2 2026 per OKUR's latest filing, from $413.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $416.9 million in Q2 2026 and bottomed at -$102.1 million in Q4 2023.
• Historically, Retained Earnings has averaged $264.7 million across 5 years, with a median of $265.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings plunged 143.12% in 2023, then soared 353.35% in 2024.
• Over 5 years, Retained Earnings stood at $236.7 million in 2022, then slumped by 143.12% to -$102.1 million in 2023, then surged by 353.35% to $258.6 million in 2024, then grew by 4.59% to $270.4 million in 2025, then jumped by 54.15% to $416.9 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $416.9 million, $413.7 million, and $270.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.